Projects per year
Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Richard Rupp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation E in Healthy Adults
Rupp, R. (PI)
Merck Sharp and Cohme Corporation ( Award # )
10/6/25 → 10/5/27
Project: Research project
-
A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age Concomitantly with Routine Pediatr
Rupp, R. (PI)
3/11/25 → 3/10/30
Project: Research project
-
Teen Health Award 2025-2027
Rupp, R. (PI)
Sealy and Smith Foundation ( Award # )
1/1/25 → 12/31/27
Project: Research project
-
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens
El Sahly, H. M., Anderson, E. J., Jackson, L. A., Neuzil, K. M., Atmar, R. L., Bernstein, D. I., Chen, W. H., Creech, C. B., Frey, S. E., Goepfert, P., Meier, J., Phadke, V., Rouphael, N., Rupp, R., Stapleton, J. T., Spearman, P., Walter, E. B., Winokur, P. L., Yildirim, I. & Williams, T. L. & 10 others, , Feb 15 2025, In: Vaccine. 47, 126689.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Mucosal and Systemic Antibody Responses after Boosting with a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
Division of Microbiology and Infectious Diseases (DMID) 21-0012 Study Group, Oct 15 2025, In: Journal of Infectious Diseases. 232, 4, p. 971-981 11 p.Research output: Contribution to journal › Article › peer-review
-
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team, Jan 15 2025, In: Clinical Infectious Diseases. 80, 1, p. 223-227 5 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team, Dec 2025, In: Nature communications. 16, 1, 759.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®
Frey, S. E., Brady, R., Jackson, L., Goepfert, P., El Sahly, H. M., Atmar, R. L., Rupp, R., Creech, C. B., Abate, G., Paulsen, G., Weiss, J., Wegel, A. & Roberts, P. C., Feb 15 2025, In: Vaccine. 47, 126702.Research output: Contribution to journal › Article › peer-review
2 Scopus citations